(Filgrastim(Axaron Bioscience)) - 药物靶点：CSF-3R_专利_临床

概要

基本信息

药物类型

生物类似药、集落刺激因子

别名

靶点

CSF-3R

作用机制

CSF-3R激动剂(巨噬细胞集落刺激因子3受体激动剂)

治疗领域

神经系统疾病心血管疾病

在研适应症-

非在研适应症

急性缺血性卒中

原研机构

Axaron Bioscience AG

在研机构-

非在研机构

Sygnis Bioscience GmbH & Co KGAxaron Bioscience AG

最高研发阶段终止临床2期

首次获批日期-

最高研发阶段(中国)-

特殊审评-

序列信息

Sequence Code 4190

当前序列信息引自: *****

关联

5

项与 Filgrastim(Axaron Bioscience) 相关的临床试验

EUCTR2010-020772-38-IT / Unknown statusN/A

A Phase II Study of Dose Density Regimen with Fluorouracil, Epirubicin and Cyclophosphamide at Days 1, 4 Every 14 Days with Filgrastim Support followed by Weekly Paclitaxel in Women with Primary Breast Cancer. - ND

开始日期2010-09-13

申办/合作机构

Istituto Scientifico Romagnolo per lo Studio e la Cura dei Tumori SRL

EUCTR2006-000891-34-BE / Unknown statusN/A

A randomized, international, open-label, phase II study of peripheral blood progenitor cell (PBPC) mobilization and engraftment with pegfilgrastim or filgrastim for autologous transplantation in subjects with multiple myeloma. - NeuMobil

开始日期2006-05-05

申办/合作机构

Hôpital Ambroise Paré

NCT00132470 / Completed临床2期

AXIS IIa - Treatment With AX200 for Acute Ischemic Stroke

The AXIS study is a randomized, double-blind, placebo-controlled, dose-escalating phase IIa trial to investigate treatment with AX200 (granulocyte-colony stimulating factor; G-CSF) for acute ischemic stroke. The primary objective of the present phase IIa study is to assess the safety and tolerability of AX200 compared to placebo in subjects suffering from acute stroke. The secondary objective is to assess the effect of AX200 on subject outcome in comparison to placebo.

开始日期2004-12-01

申办/合作机构

Axaron Bioscience AG

100 项与 Filgrastim(Axaron Bioscience) 相关的临床结果

登录后查看更多信息

100 项与 Filgrastim(Axaron Bioscience) 相关的转化医学

登录后查看更多信息

100 项与 Filgrastim(Axaron Bioscience) 相关的专利（医药）

登录后查看更多信息

8

项与 Filgrastim(Axaron Bioscience) 相关的文献（医药）

2021-03-01·Stroke1区 · 医学

Imaging Markers of Brain Frailty and Outcome in Patients With Acute Ischemic Stroke

1区 · 医学

Article

作者: Grond, Martin ; Norrving, Bo ; Thijs, Vincent ; Lemmens, Robin ; Ringelstein, E. Bernd ; Wilms, Guido ; Laage, Rico ; Chamorro, Angel ; Fiebach, Jochen B. ; Bu, Ning ; Khlif, Mohamed Salah ; Wouters, Anke ; Brodtmann, Amy

Background and Purpose:Functional outcome after stroke may be related to preexisting brain health. Several imaging markers of brain frailty have been described including brain atrophy and markers of small vessel disease. We investigated the association of these imaging markers with functional outcome after acute ischemic stroke.Methods:We retrospectively studied patients with acute ischemic stroke enrolled in the AXIS-2 trial (AX200 in Ischemic Stroke Trial), a randomized controlled clinical trial of granulocyte colony-stimulating factor versus placebo. We assessed the ratio of brain parenchymal volume to total intracerebral volumes (ie, the brain parenchymal fraction) and total brain volumes from routine baseline magnetic resonance imaging data obtained within 9 hours of symptom onset using the unified segmentation algorithm in SPM12. Enlarged perivascular spaces, white matter hyperintensities, lacunes, as well as a small vessel disease burden, were rated visually. Functional outcomes (modified Rankin Scale score) at day 90 were determined. Logistic regression was used to test associations between brain imaging features and functional outcomes.Results:We enrolled 259 patients with a mean age of 69±12 years and 46 % were female. Increased brain parenchymal fraction was associated with higher odds of excellent outcome (odds ratio per percent increase, 1.078 [95% CI, 1.008–1.153]). Total brain volumes and small vessel disease burden were not associated with functional outcome. An interaction between brain parenchymal fraction and large vessel occlusion on excellent outcome was not observed.Conclusions:Global brain health, as assessed by brain parenchymal fraction on magnetic resonance imaging, is associated with excellent functional outcome after ischemic stroke.Registration: URL: https://www.clinicaltrials.gov . Unique identifier: NCT00927836.

2016-03-14·The Medical letter on drugs and therapeutics4区 · 医学

Zarxio--a filgrastim biosimilar.

4区 · 医学

Review

2015-10-01·Journal of Cerebral Blood Flow & Metabolism2区 · 医学

Association between the Perfusion/Diffusion and Diffusion/FLAIR Mismatch: Data from the AXIS2 Trial

2区 · 医学

Article

作者: Dupont, Patrick ; Chamorro, Angel ; Norrving, Bo ; Wouters, Anke ; Schneider, Armin ; Thomalla, Götz ; Ringelstein, Erich B ; Lemmens, Robin ; Wilms, Guido ; Thijs, Vincent N ; Grond, Martin ; Laage, Rico

The perfusion-/diffusion-weighted imaging (PWI/DWI) mismatch and the diffusion/fluid attenuated inversion recovery (DWI/FLAIR) mismatch are magnetic resonance imaging (MRI) markers of evolving brain ischemia. We examined whether the DWI/FLAIR mismatch was independently associated with the PWI/DWI mismatch. Furthermore, we determined whether the presence of the DWI/FLAIR mismatch in patients with the PWI/DWI mismatch would provide additional information regarding last seen normal time (LTM). We used data from the ‘AX200 for ischemic stroke’ trial (AXIS 2 study NCT00927836). We studied the association between the presence of the DWI/FLAIR and PWI/DWI mismatch, baseline National Institute of Health Stroke Scale (NIHSS), age, ischemic-core volume, gender, intravenous (IV) tissue plasminogen activator (tPA), and perfusion-mismatch volume in univariate analysis. Significant variables ( P < 0.05) were added into the final multivariate model. We analyzed 197 patients. Seventy-two (37%) had both the PWI/DWI and the DWI/FLAIR mismatch. Patients with the double mismatch pattern had a shorter LTM than patients with the PWI/DWI mismatch alone (Median difference 90 minutes, P < 0.01). Multivariate analysis confirmed the independent association between the two mismatch patterns (odds ratio (OR) 2.6, 95% confidence interval (CI) 1.2 to 5.4). Our study implies that the DWI/FLAIR mismatch and PWI/DWI mismatch are strongly associated, independent from LTM. Furthermore, in the presence of the PWI/DWI mismatch, the DWI/FLAIR pattern indicates a shorter LTM. This could have implications in selecting patients for reperfusion therapy.

100 项与 Filgrastim(Axaron Bioscience) 相关的药物交易

登录后查看更多信息

研发状态

10 条进展最快的记录,

登录

后查看更多信息

适应症	最高研发状态	国家/地区	公司	日期
急性缺血性卒中	临床2期	德国	Axaron Bioscience AG	2004-12-01
急性缺血性卒中	临床1期	德国	Axaron Bioscience AG	2004-12-01

登录后查看更多信息

临床结果

适应症

分期

评价

查看全部结果

研究	分期	人群特征	评价人数	分组	结果	评价	发布日期


EHA2017	N/A	毛细胞白血病	202	Pegfilgrastim	網憲製遞繭齋艱繭窪衊(鏇鏇鑰襯網蓋積淵艱積) = 遞遞繭簾範醖淵艱構壓遞淵觸鹹憲憲遞獵鑰鹽 (廠積願憲繭糧廠醖鏇選 )	-	2017-05-18
				Filgrastim	網憲製遞繭齋艱繭窪衊(鏇鏇鑰襯網蓋積淵艱積) = 窪製淵蓋襯觸餘鬱鹽廠遞淵觸鹹憲憲遞獵鑰鹽 (廠積願憲繭糧廠醖鏇選 )
ASCO2019	N/A	前列腺癌	65	As-needed filgrastim (ANF)	鹹製艱觸範願蓋憲遞構(築築壓鹽淵窪醖鹽製衊) = 衊廠鹽積淵餘鑰築憲鹽窪簾憲膚構鬱顧範簾觸 (鹽鬱簾餘齋觸願選齋獵 ) 更多	积极	2019-05-26
				Prophylactic pegfilgrastim (PPF)	鹹製艱觸範願蓋憲遞構(築築壓鹽淵窪醖鹽製衊) = 夢鏇憲選構鹹積網憲繭窪簾憲膚構鬱顧範簾觸 (鹽鬱簾餘齋觸願選齋獵 ) 更多
TULIP (ASCO2016)	N/A	肿瘤	1,119	Filgrastim	窪壓艱憲襯觸齋艱積積(築鬱網遞鹽憲範廠顧積) = 製願獵築衊觸繭鹹鹽選簾鏇衊艱網積齋蓋鑰壓 (憲淵膚鹽醖簾鬱鏇積蓋 ) 更多	积极	2016-05-20
ASCO2022	N/A	肿瘤	179	Bevacizumab	網蓋鏇範廠壓鏇繭鏇繭(顧築膚餘艱襯齋築製鬱) = Medication errors related to biosimilar use were reported by 26% respondents, with the most common cause listed as communication. 範鬱遞範艱壓願獵艱艱 (鑰鏇憲範鏇鬱鏇廠製鬱 )	-	2022-06-02
				Filgrastim
ESMO_ASIA2022	N/A	化疗引起的发热性中性粒细胞减少症	112	Filgrastim	(積願網襯夢蓋鏇製鏇簾) = 獵衊鹹積構餘蓋簾窪繭遞鏇積觸構廠廠膚膚餘 (獵積餘蓋鹽鏇衊夢窪鹽 ) 更多	-	2022-12-03
				Pegfilgrastim	(積願網襯夢蓋鏇製鏇簾) = 鹽構繭鏇壓衊鑰夢淵憲遞鏇積觸構廠廠膚膚餘 (獵積餘蓋鹽鏇衊夢窪鹽 ) 更多
EHA2015	N/A	B细胞淋巴瘤	177	Filgrastim	鏇醖艱鹽選廠選鬱壓網(醖觸襯鹽餘鹽積壓觸鏇) = 壓憲襯窪醖淵襯廠膚夢襯願觸襯顧壓齋鏇壓淵 (蓋鹹顧顧鹽衊觸膚觸製 ) 更多	-	2015-05-21
ASCO2020	N/A	多发性骨髓瘤	57	Pegfilgrastim	(製積顧製淵廠襯製壓觸) = main side effects were mild fever and bone pain (21.2%) 願糧醖觸淵鏇壓膚觸憲 (獵簾襯鏇鑰範繭構齋觸 )	积极	2020-05-25
				Filgrastim
ESMO2019	N/A	肉瘤	79	Filgrastim	網襯艱鬱繭廠壓壓齋糧(蓋憲遞鑰鏇蓋製鑰網鏇) = The use of peg-F was associated with a significantly higher rate of neutropenic infections requiring hospitalization compared with F in adult sarcoma pts receiving HMC 顧膚廠艱鬱鏇襯鹽壓構 (壓醖選遞蓋選範製積築 )	-	2019-09-28
				Pegfilgrastim
NCT03441048 (ASCO2023) 人工标引	临床1期	难治性急性髓细胞白血病	19	Lintuzumab-Ac225+Cladribine+Cytarabine+Filgrastim+Mitoxantrone (High-risk population)	(鏇簾鬱齋衊窪憲繭網廠) = 廠顧積獵蓋築艱繭顧淵簾廠醖壓選製鹽夢築顧 (淵築範願廠遞夢製襯艱 ) 更多	积极	2023-05-26
				Lintuzumab-Ac225+Cladribine+Cytarabine+Filgrastim+Mitoxantrone (ELN Adv Risk)	(鏇簾鬱齋衊窪憲繭網廠) = 鏇艱糧衊艱顧鹹構選鹹簾廠醖壓選製鹽夢築顧 (淵築範願廠遞夢製襯艱 ) 更多
EHA2019	N/A	干细胞动员	40	Once-daily filgrastim (1*10 mcg/kg)	衊顧鹹鹹製製鑰獵壓觸(鬱壓鹹壓襯鏇製願衊蓋) = 製觸繭夢糧鬱鏇齋範鏇衊憲獵齋築廠網選醖願 (觸蓋鹹糧壓衊鑰蓋鹽膚 )	-	2019-05-16
				Twice-daily filgrastim (2*5 mcg/kg)	衊顧鹹鹹製製鑰獵壓觸(鬱壓鹹壓襯鏇製願衊蓋) = 艱繭憲憲艱遞鬱範醖築衊憲獵齋築廠網選醖願 (觸蓋鹹糧壓衊鑰蓋鹽膚 )